Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RDY
RDY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest RDY ETF News Today | Earnings, Events & Price Alerts
RDY News
Dr. Reddy's Laboratories Seeks FDA Approval for Orencia Biosimilar
Feb 20 2026
seekingalpha
Dr. Reddy's Submits Biosimilar Application for Review
Feb 20 2026
Businesswire
Dr. Reddy's Submits Biosimilar Application for Abatacept
Feb 20 2026
Newsfilter
Dr. Reddy's Submits Biosimilar Application for Abatacept
Feb 20 2026
Yahoo Finance
Dr. Reddy's Receives USFDA Approval to Review Biologics License Application for Proposed Interchangeable Biosimilar Abatacept
Feb 20 2026
moomoo
Coya Therapeutics Secures $11.1 Million in Private Placement
Jan 30 2026
Yahoo Finance
Dr. Reddy's Laboratories (RDY) Reports Q3 EPS of ₹14.52 and Revenue of ₹87.27 Billion
Jan 22 2026
seekingalpha
Dr. Reddy's Laboratories (RDY) Secures Approval for Generic Ozempic, Plans to Produce 12M Pens in First Year
Jan 21 2026
seekingalpha
Asian Equities Surge as American Depositary Receipts Rise Sharply
Jan 21 2026
Yahoo Finance
Dr. Reddy's (RDY) to Announce Q3 Earnings on January 21, 75% EPS Beat Rate
Jan 20 2026
seekingalpha
Dr. Reddy's Launches 0.7% Olopatadine OTC Eye Drops with $69.9M Market Potential
Jan 14 2026
Businesswire
ReadyTech Holdings: 54% Shares Controlled by Top 4 Shareholders
Jan 01 2026
Yahoo Finance
Zacks Industry Outlook Spotlights Sandoz, Teva Pharmaceuticals, and Dr. Reddy's
Dec 09 2025
NASDAQ.COM
Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment
Dec 08 2025
Newsfilter
Dr. Reddy's Laboratories Hits Oversold Status (RDY)
Oct 31 2025
NASDAQ.COM
Dr. Reddy's Laboratories Sees Increase in Q2 Profit
Oct 25 2025
NASDAQ.COM
Show More News
